Navigation Links
Companion Diagnostics in Personalized Medicine and Cancer Therapy
Date:8/6/2014

LONDON, Aug. 6, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Companion Diagnostics in Personalized Medicine and Cancer Therapy

http://www.reportbuyer.com/pharma_healthcare/diseases/cancer/companion_diagnostics_personalized_medicine_cancer_therapy.html

Companion diagnostics (CDx) refers to a particular clinical diagnostic test that is under evaluation and is specifically linked to a known drug therapy. This linkage could be important in the therapeutic application and clinical outcome of a drug, such as with personalized medicine for oncology patients. The molecular diagnostics field plays a vital part in personalized medicine and has greatly expanded over the past twenty years, expanding by more than 20% annually compared to most other laboratory procedures. Research will continue to produce an increased understanding of disease processes, and diagnostics manufacturers will continue to expand and refine the technology and automation needed for clinical testing. Companion diagnostics, although smaller at present, is one of the fastest growing segments in the in vitro diagnostic (IVD) market. And while the concept of a drug-diagnostic combination is not new, it has only recently started to generate interest with the move of healthcare towards pharmacogenomics. This TriMark Publications report examines the use of companion diagnostics in personalized medicine and cancer therapy. The study provides a qualitative and quantitative review of the industry, including cancer biomarker tests, pharmacogenomics tests, recurrence prediction tests, blood-based technologies, proteomics and regulatory trends. Moreover, this analysis profiles the leading companies that are developing and manufacturing companion diagnostics solutions. Each company is discussed in extensive depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position. Detailed tables and charts with sales forecasts and market share data are also included.

TABLE OF CONTENTS
1. Overview 9
1.1 Statement of Report 9
1.2 About This Report 9
1.3 Scope of the Report 10
1.4 Objectives 11
1.5 Methodology 12
1.6 Executive Summary 13

2. Companion Diagnostics: Trends and Overview 19
2.1 Stakeholders in Companion Diagnostics 19
2.2 Development of Stakeholders' Business Models for Companion Diagnostics for Personalized
Medicine 21
2.2.1 Pharmaceutical Company Business Models for Developing Companion Diagnostics Products 21
2.2.2 Diagnostic Company Business Models for Developing Companion Diagnostics Products 22
2.2.3 Life Science Company Business Models for Developing Companion Diagnostics Products 22
2.2.4 Pharmacy Benefit Management Company Business Models for Developing Companion Diagnostics Products 23
2.3 Trends in Companion Diagnostic Deals 23
2.4 Market Size of Companion Diagnostics 24

2.5 Companion Diagnostics: Industry SWOT Analysis 31
2.6 Challenges for Companion Diagnostics Development 31
2.7 Timeline for Impact of Various Segments in Companion Diagnostics 33
2.8 Use of Proteomics to Develop Individualized Tests 35

3. Companion Diagnostics: Qualitative and Quantitative Market Analysis 38
3.1 Market Analysis of Molecular Diagnostics and Companion Diagnostics 38
3.2 Costs of Companion Diagnostics in Healthcare Expenditures 40
3.3 Molecular Diagnostic Market 41
3.4 Molecular Diagnostics Technology Platforms and Their Impact on Clinical Medicine 43
3.5 Snapshot of Companion Diagnostics Industry Structure 45
3.6 The Case for Theranostics 46
3.7 Companion Diagnostics Market Analysis 47

4. Biomarker Tests Co-developed with Cancer Therapeutics as Companion Diagnostics 49
4.1 Sector Overview 49
4.1.1 Impact of New Technology Platforms 49
4.1.2 Impact on Drug Discovery 49
4.1.3 Biomarkers as Endpoints in Drug Discovery 50
4.1.4 Targeted Therapy 51
4.2 Companion Diagnostics on the Market 51
4.3 Epidermal Growth Factor Receptor Companions 53
4.3.1 Bevacizamab (Avastin) 54
4.3.2 EGFR for CRC and Camptosar (Irinotecan) 55
4.3.2.1 Companion Diagnostic Test Developed for UGT1A1 for Irinotecan 55
4.3.2.2 Companion Diagnostic Test Developed for Bristol-Myers' SPRYCEL 55
4.3.3 EGFR Express and Erbitux (Cetuximab) 55
4.3.4 HER2 and Herceptin (Trastuzumab) 56
4.3.4.1 Bayer's Advia Centaur HER2/neu Assay 58
4.3.4.2 Companies Marketing HER2/neu Assays 58
4.3.5 Iressa and Tarceva Companion Test 58
4.3.6 Tykerb (GlaxoSmithKline (GSK)) and Vectibix (Amgen) Companion Tests 58
4.3.7 EGFRx Assay 59
4.3.8 Monogram eTag 59
4.3.9 Veripath OncoDiagnostics EGFR PharmDX 60
4.3.10 NSCLC Patients with EGFR Mutation 60
4.3.11 A Personalized Medicine Program for CML 60
4.4 Companions Based on Myriad's IVDMIA Technology 61
4.4.1 Myriad's TheraGuide 5-FU 61
4.4.2 Myriad's BRACAnalysis: Hereditary Cancer Testing for Hereditary Breast and Ovarian Cancer 61

4.5 Companions for Tyrosine Kinase Inhibitors: Erlotinib and Gefitinib 62
4.5.1 TheraScreen: EGFR29 62
4.5.2 The K-RAS Mutation Detection Kit 62
4.6 Irinotecan and UGT1A1 62
4.7 Gleevec (Imatinib) Companions 63
4.7.1 DakoCytomation's c-Kit (9.7) pharmDx 63
4.8 Companion Diagnostics Involving Metabolizing Enzymes 64
4.8.1 Companions for TMPT, CYP2C9 and UGT1A1 Enzymes 64
4.8.2 Companions for Aromatase Inhibitors 64
4.8.3 Companions for Actos and Avandia 65
4.9 Drivers and Barriers to Companion Diagnostics 65
4.10 Partnerships with Pharma Companies to Identify Therapeutic Targets 66
4.11 Circulating Tumor Cell Assay: Prognostic and Predictive Factors for Breast Cancer 66
4.12 Companion Diagnostics Used by Clinical Service Laboratories 67
4.13 New Technologies and Products under Development 68
4.13.1 MDx Health 69
4.13.2 Ventana to Collaborate with Pfizer and CST on Companion Diagnostic to Identify Lung Cancer Patients with ALK Gene Rearrangements 70
4.13.3 Abbott and Merck Collaborate to Develop Companion Diagnostic Test for Investigational Cancer
Therapy 70
4.14 Pharmacogenomics Tests 71
4.14.1 MGMT Methylation Assay 71
4.14.2 Other Pharmacogenomic Opportunities 72
4.15 Recurrence Prediction Tests 73
4.16 Blood-Based Technologies 73
4.16.1 Oncotech, Inc. 73
4.17 Monogram Biosciences HIV Personalized Platform 74
4.18 Wako LBA AFP Test for Liver Cancer 74
4.19 Future Developments for Companion Diagnostics 74
4.20 Drug Response Predictors 76

5. Business and Regulatory Trends in the Companion Biomarker Testing Sector 77
5.1 Industry Consolidation 77
5.2 Breath of Product Offering and Pricing 78
5.3 Government Regulation of Medical Devices 78
5.3.1 FDA Guidance on Drug Test Co-development 80

5.3.2 Device Classes 80
5.3.3 Investigational Use of IVDMIAs 81
5.3.4 Post-Market Requirements 81
5.3.5 Voluntary vs. Required Submissions 82
5.3.6 Examples of Recent Voluntary Genomic Data Submissions 82
5.3.7 FDA Labeling Implications and Rules 82
5.3.8 Regulatory Activities in Companion Diagnostic Testing—Translation of Diagnostic Testing Results into Clinical Practice 83
5.4 Strategic Business and Marketing Considerations 83
5.5 Commercial Opportunities in Companion Markers 83
5.6 Moderators of Growth 85
5.6.1 Roadblocks to Integrating Companion Biomarkers into Clinical Practice 86
5.6.2 Management of Targeted Therapeutics by Third-Party Payers 86
5.7 Biotechnology Industry Trends 87
5.8 Pharmaceutical Industry Trends 87
5.9 Acquisition, License Agreement, Partnerships 88
5.10 Legal Developments 94
5.11 Sales and Marketing Strategies for Tumor Marker Tests 95
5.11.1 International Markets 97
5.11.2 Europe 97
5.11.3 Central and South America 98
5.11.4 Asia-Pacific 98
5.12 Product Commercialization 99
5.13 Reimbursement 100
5.14 Self-Referral Rules 101
5.15 Health Insurance Portability and Accountability Act 102

5.16 Clinical Laboratory Improvement Amendments (CLIA) 102
5.17 In Vitro Diagnostic Directive (IVDD) and Medical Device Regulations 103
5.18 FDA's Quality System Regulation (QSR) 104
5.19 The FDA's OIVD on IVDMIAs 104
5.20 FDA's Qualification of Cancer Biomarkers 105
5.20.1 Regulatory Perspectives of Biomarker Validation 105
5.21 Genetic Tests and Medical Records 106
5.21.1 Laws Against Genetic Discrimination 107
5.22 Global Drivers of Clinical Laboratory Testing 107
5.23 Global Outlook 108
5.24 Oncology Biomarker Qualification Initiative 109
5.25 FDA Critical Path 109
5.26 Biomarkers and FDA's Voluntary Genomic Data Submission 110
5.27 From Personalized to Predictive Medicine 110
5.28 Analysis of Cost-Effectiveness at the Individual Level 110
5.29 The Patient and Advocate Perspective: An Evolution of Influence 110
5.30 Real-World Experiences Translating the Vision of Personalized Medicine into Practice 110
5.30.1 Evolving Business Models in Companion Diagnostics and Personalized Medicine 111
5.30.2 Current Pharma/Diagnostics Business Model Examples 112
5.31 Reimbursement and Value Creation 112
5.32 What is the Role of Governmental Agencies in Driving the Adoption of Companion Diagnostics? 112
5.33 What is the Role of the Insurance Industry in Driving the Adoption of Pharmacogenomics (PGx)? 112
5.34 What is the Role of the Pharma Industry in Driving the Adoption of PGx? 113
5.35 FDA Guidance Document on Co-development 113
5.36 What is the Role of the Diagnostic Industry in Driving the Adoption of PGx? 113
5.37 What is the Future Role of PBMs in Laboratory Services? 114

6. Companion Diagnostics and Personalized Medicine 115
6.1 Scope of This Section 115
6.2 Introduction to Companion Diagnostics and Personalized Medicine 115
6.3 Drug Metabolism, Companion Diagnostics and Personalized Medicine 122
6.4 Examples of Personalized Medicine and Companion Diagnostic Tests 125
6.5 Personalized Medicine and Companion Diagnostic Testing Product Pipeline 130

6.6 The Personalized Medicine Coalition (PMC) 132
6.7 Regulatory Trends and Guidelines in the Personalized Medicine Space 137
6.7.1 The Changing Regulatory Landscape for Personalized Medicine 138
6.8 Companion Diagnostics Play an Increasing Role in Cancer Care 140
6.9 Specific Examples of Clinical Situations where Companion Diagnostics are being Deployed 140
6.9.1 Epidermal Growth Factor Receptor Assay 141
6.9.2 Individualized Warfarin Therapy 143
6.9.3 UGT1A1 Molecular Assay for Camptosar 144
6.9.4 Response to Gleevec in Gastrointestinal Stromal Tumors (GISTs) 144
6.9.5 LabCorp and QIAGEN and Personalized Medicine for the treatment of Colorectal Cancer 144
6.9.6 LabCorp and ARCA Discovery, Inc. Personalized Medicine for Cardiovascular Disease 145
6.9.7 Roche's Metastatic Melanoma Treatment, Zelboraf (Vemurafenib) 145
6.9.8 Abbott's Late-Stage NSCLC Treatment, Xalkori (Crizotinib) 146
6.10 Diagnostic Tests for Personalized Analysis of Cancer Therapy Effectiveness 146
6.11 Value Chain 147
6.12 Impact of Companion Diagnostics/Personalized Medicine on Drug Clinical Trials 148
6.13 The Market Problem: Finding Value with Diagnostics for Personalized Medicine 149

7. Companies Entering the Companion Diagnostics Market 150
7.1 Industry Overview 150
7.1.1 20/20 GeneSystems, Inc. 152
7.1.2 Abbott Molecular, Inc. 153
7.1.3 Affymetrix, Inc. 156
7.1.4 Agendia BV 164
7.1.5 Agilent Technologies 166
7.1.6 Almac Group 167
7.1.7 AMDL, Inc. (Radient Pharmaceuticals) 169

7.1.8 Applied Biosystems 171
7.1.9 Asuragen, Inc. 172
7.1.10 Aureon Laboratories, Inc. 173
7.1.11 Beckman Coulter, Inc. (Danaher Corporation) 175
7.1.12 Becton, Dickinson and Company (BD) Diagnostics—TriPath 178
7.1.13 Biocode Hycel (Immunodiagnostics Systems [IDS]) 180
7.1.14 BioCurex, Inc. 180
7.1.15 Biodesix 181
7.1.16 Biomarker Technologies, LLC 181
7.1.17 Biomedical Diagnostics, LLC 182
7.1.18 Biomerica, Inc. 182
7.1.19 bioMérieux, Inc. 183
7.1.20 Biomira, Inc. (Oncothyreon, Inc.) 184
7.1.21 BioModa, Inc. 185
7.1.22 Bruker Daltonics 186
7.1.23 Byk Gulden 186
7.1.24 Cangen Biotechnologies, Inc. 186
7.1.25 Caprion Proteomics 188
7.1.26 Celera Diagnostics 190
7.1.27 Cepheid, Inc. 191
7.1.28 Clarient, Inc. (GE Healthcare) 193
7.1.29 Claros Diagnostics, Inc. 194
7.1.30 Clinical Data, Inc.: PGxHealth and Cogenics 194
7.1.31 Correlogic Systems, Inc. 197
7.1.32 CytoCore, Inc. (Formerly known as Molecular Diagnostics, Inc.) 197
7.1.33 Cytogen Corporation (now EUSA Pharma) 198

7.1.34 Dako (Agilent Technologies) 199
7.1.35 diaDexus 200
7.1.36 DiagnoCure 201
7.1.37 DRG International 203
7.1.38 EDP Biotech Corporation 204
7.1.39 Eisai Co., Ltd. 205
7.1.40 Eli Lilly & Co. 205
7.1.41 Epigenomics 206
7.1.42 Exact Sciences Corporation 207
7.1.43 Exagen Diagnostics, Inc. 208
7.1.44 Exigon 208
7.1.45 Gene Logic, Inc. 208
7.1.46 Genesis Genomics, Inc. (now known as Mitomics) 209
7.1.47 GenMark Diagnostics 210
7.1.48 Genomic Health, Inc. 211
7.1.49 Gen-Probe, Inc. (now known as Hologic Gen-Probe ) 212
7.1.50 Health Discovery Corporation 216
7.1.51 Ikonisys, Inc. 217
7.1.52 Illumina 218
7.1.53 Immunomedics 220
7.1.54 InterGenetics, Inc. 222
7.1.55 Ipsogen (QIAGEN Marseille) 222
7.1.56 Johnson & Johnson 224
7.1.57 LabCorp 225
7.1.58 Life Technologies Corporation (Thermo Fisher Scientific) 227
7.1.59 Matritech, Inc. 229
7.1.60 Miraculins 230

7.1.61 Mitsubishi Kagaku latron 231
7.1.62 Monogram Biosciences (Formerly ViroLogic, Inc. and now part of LabCorp) 231
7.1.63 Myriad Genetics, Inc. 232
7.1.64 NimbleGen Systems, Inc. 235
7.1.65 Northwest Biotherapeutics, Inc. 236
7.1.66 Novartis MDx 237
7.1.67 Nycomed (Takeda) 238
7.1.68 Oncotech, Inc. (Exiqon A/S) 239
7.1.69 Oncothyreon, Inc. (Formerly known as Biomira) 239
7.1.70 OPKO Health, Inc. 241
7.1.71 Orion Genomics 243
7.1.72 Oxford BioTherapeutics (Formerly Oxford Genome Sciences) 244
7.1.73 Panacea Pharmaceuticals, Inc. 245
7.1.74 Polymedco, Inc. 245
7.1.75 Power3 Medical Products 246
7.1.76 Prometheus Laboratories, Inc. (Nestlé Health Science S.A) 247
7.1.77 Proteome Systems Ltd. (Tyrian Diagnostics Ltd.) 247
7.1.78 Qiagen N.V. 248
7.1.79 Roche Molecular Diagnostics 252
7.1.80 Sanko Junyaku Co., Ltd. (Eisai Co., Ltd.) 254
7.1.81 SensiGen, LLC (Sequenom Center for Molecular Medicine) 255
7.1.82 Siemens Healthcare Diagnostics, Inc. 255
7.1.83 SuperArray Bioscience Corporation (Qiagen) 257
7.1.84 Third Wave Technologies, Inc. (now owned by Hologic Gen-Probe) 257
7.1.85 Tosoh Biosciences 259
7.1.86 Transgenomic, Inc. 259

7.1.87 TrimGen 259
7.1.88 Upstream Biosciences, Inc. (RealSource Residential, Inc.) 260
7.1.89 Ventana Medical Systems, Inc. 260
7.1.90 Veridex, LLC 262
7.1.91 Vermillion, Inc. (Formerly Ciphergen) 263
7.1.92 Vertex Pharmaceuticals, Inc. 263

Appendix 1: FDA Guidance for Industry: Pharmacogenomic Data Submissions 265
Appendix 1.1: Introduction 265
Appendix 1.2: Background 265
Appendix 1.3: Submission Policy 266
Appendix 1.3.1: General Principles 266
Appendix 1.3.2: Specific Uses of Pharmacogenomic Data in Drug Development and Labeling 268
Appendix 1.3.3: Benefits of Voluntary Submissions to Sponsors and FDA 269
Appendix 1.4: Submission of Pharmacogenomic Data 269
Appendix 1.4.1: Submission of Pharmacogenomic Data During the IND Phase 270
Appendix 1.4.2: Submission of Pharmacogenomic Data to a New NDA, BLA or Supplement 271
Appendix 1.4.3: Submission to a Previously Approved NDA or BLA 272
Appendix 1.4.4: Compliance with 21 CFR Part 58 272
Appendix 1.4.5: Submission of Voluntary Genomic Data from Application-Independent Research 272
Appendix 1.5: Format and Content of a VGDS 273
Appendix 1.6: Process for Submitting Pharmacogenomic Data 274
Appendix 1.7: Agency Review of VGDSs 274
Appendix 2: FDA Issues Draft Companion Diagnostic Guidance 276
Appendix 3: Histochemical Markers for Cancer 278
Appendix 4: E16 Biomarkers Related to Drug or Biotechnology Product Development: Context, Structure, and Format of Qualification Submissions 279

Appendix 4.1: Introduction 279
Appendix 4.2: Background 279
Appendix 4.3: Scope 279
Appendix 4.4: General Principles 279
Appendix 4.5: Structure of Biomarker Qualification Submissions 280
Appendix 5: Selected Personalized Medicine Drugs, Treatments and Diagnostics as of June 2014 287
Glossary 292


INDEX OF FIGURES

Figure 2.1: Strategic and Tactical Considerations for Co-Development of Companion Diagnostics 24
Figure 2.2: Global Market for Companion Diagnostics, 2012-2019 25
Figure 2.3: Number of Companion Diagnostic Agreements, 2000-2013 26
Figure 2.4: Surface Binding Produces Phase Shifts that Increases the Diffraction Signal Intensity 36
Figure 3.1: From Genetic Content to Personalized Medicine 39
Figure 3.2: Impact of Diagnostic Testing on Healthcare Decision-Making 40
Figure 3.3: Impact of Diagnostic Testing on Healthcare Spending 40
Figure 3.4: Breakout of the Molecular Diagnostics Marketplace 42
Figure 3.5: Molecular Diagnostics Market Segmentation 43
Figure 3.6: Molecular Diagnostics Market Segmentation by Technology 43
Figure 3.7: Segmentation of the Personalized Medicine Market 47
Figure 4.1: Carcinogenesis is a Multi-Step Process 54
Figure 4.2: ASCO-CAP Guidelines for HER2 Testing in Breast Cancer: Equivocal Results with IHC 57
Figure 4.3: ASCO-CAP Guidelines for HER2 Testing in Breast Cancer: Results by FISH 57

Figure 5.1: Companion Diagnostics Partnering, 2007-2013 88
Figure 5.2: Companion Diagnostics Partnering by Stage of Development, 2013 89
Figure 5.3: Companion Diagnostics Partnering by Therapeutic Area, 2013 90
Figure 6.1: U.S. Healthcare Expenditures by Category of Service, 2010 116
Figure 6.2: Representation of the Trial-and-Error or One-Dose-Fits-All Approach vs. Personalized
Medicine 116
Figure 6.3: Approaches to Personalized Medicine 118
Figure 6.4: Organizational Transformation to Support Personalized Medicine, 1998-2013 119
Figure 6.5: The Phase I and II Processes of Drug Metabolism 122
Figure 6.6: Hepatic Distribution of Human CYP450 123
Figure 6.7: Relative Contribution of CYP450 Enzymes to Drug Metabolism 123
Figure 6.8: Genetic Components Determine Drug Metabolism 124
Figure 6.9: Personalized Medicine Clinical Trials by Year, 1993-2008 129
Figure 6.10: Healthcare Value Chain 147


INDEX OF TABLES

Table 2.1: FDA Approved Companion Diagnostic Devices: In Vitro and Imaging Tools 26
Table 2.2: Personalized Medicine Industry SWOT Analysis 31
Table 2.3: Hurdles to Personalized Medicine and Companion Diagnostics Development 32
Table 2.4: Timeline of Impact in Areas of Personalized Medicine 33
Table 2.5: Impact of Personalized Medicine on Various Therapeutic Areas 34
Table 3.1: Diagnostic Facts 39
Table 3.2: Timeline for Impact of Various Molecular Diagnostics Technologies on Personalized Medicine 44
Table 3.3: Impact of Molecular Diagnostics Technologies on Therapeutic Areas in Personalized Medicine 44
Table 3.4: Challenges of Various Molecular Diagnostics Technology Platforms in Personalized Medicine 45
Table 3.5: FDA Classification of Diagnostics by Risk 47
Table 4.1: Potential Benefits of Biomarkers as Companion Diagnostics 50
Table 4.2: Utility of Biomarker as Companion Diagnostics to Drug Development 51
Table 4.3: ASCO-CAP Guidelines for HER2 Testing in Breast Cancer: How to Interpret Test Results 56
Table 4.4: Drivers of Companion Diagnostics Discovery 65
Table 4.5: Barriers to Companion Diagnostics Discovery 66
Table 4.6: Device Submission Elements for the FDA 66
Table 5.1: List and Discounted Prices for Abbott Tumor Marker Tests 78
Table 5.2: Recent Major Companion Diagnostics Deals 89

Table 5.3: Summary of Biomarker Use in the Commercialization of Novel Oncology
Pharmacotherapeutics 111
Table 5.4: Pharmacoeconomic Challenges to the Implementation of Biomarkers as Companion
Diagnostic Tests 111
Table 6.1: Timeline for Development of Companion Diagnostics 118
Table 6.2: Personalized Medicine at the Nexus Point 120
Table 6.3: Percentage of Non-Responders in Various Drug Classes 120
Table 6.4: High-Profile Drug Withdrawals from the Marketplace 121
Table 6.5: Metabolism of Drugs by Hepatic Enzymes 122
Table 6.6: Drug Metabolism Drives Drug Efficacy/Toxicity 125
Table 6.7: Population Frequency of the Various Cytochromes 125
Table 6.8: Selected List of Personalized Medicine Tests 128
Table 6.9: Personalized Medicine and Companion Diagnostics Product Pipeline 131
Table 6.10: Members of the Personalized Medicine Coalition 133
Table 6.11: Typical Response Rates in Therapeutic Areas 141
Table 6.12: Prevalence of People Taking Medications Metabolized by Liver Enzymes 142
Table 6.13: UGT1A1 Helps to Determine Risks Associated with Irinotecan 142
Table 6.14: Current Product Labels: Enzyme Metabolism 143
Table 7.1: Major Players in Companion Diagnostics Sector and Summary List of Companion Diagnostics Agreements 150
Table 7.2: Major GeneChip Instrument Products 159
Table 7.3: Major GeneChip Array and Reagent Products 160

Table 7.4: Gene Titan Products 160
Table 7.5: Gene Atlas Products 160
Table 7.6: Gene Atlas Products 161
Table 7.7: Opportunities for Biomarkers in Cancer Diagnosis and Treatment 193
Table 7.8: Tumor Diagnosis Immunoassay 204
Table 7.9: Tumor Diagnosis Radioimmunoassay 204
Table 7.10: Johnson & Johnson Financial Figures—Net Sales by Major Medical and Diagnostics Businesses,
2010-2013 224
Table 7.11: Roche Group Financial Figures—Net Sales by Business Sector, 2008-2013 254
Table 7.12: Roche Group Diagnostics Division—Net Sales by Geographic Region, 2012 and 2013 254
Table 7.13: Roche Group Financial Figures—Net Sales by Diagnostics Sub-Division, 2008-2013 254

Read the full report:
Companion Diagnostics in Personalized Medicine and Cancer Therapy

http://www.reportbuyer.com/pharma_healthcare/diseases/cancer/companion_diagnostics_personalized_medicine_cancer_therapy.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com


'/>"/>
SOURCE ReportBuyer
Copyright©2014 PR Newswire.
All rights reserved


Related medicine technology :

1. Ventana paves the way for companion diagnostic early phase clinical trials in China to advance patient care
2. QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients
3. Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment
4. Ventana announces HER2 companion diagnostic to identify breast cancer patients for Roches latest targeted medicines, Perjeta and Kadcyla
5. Ventana to partner with Incyte on the development of Companion Diagnostic tests
6. Kennel Cough is in Season all Year for our Canine Companions
7. Harrisvaccines, Inc. Secures Exclusive Rights From AlphaVax, Inc. to Develop RNA Particle Vaccines for All Diseases in Companion Animals
8. Ventana receives approval from Chinas FDA for first fully automated IHC companion diagnostic identifying ALK protein expression in lung cancer patients
9. Companion Diagnostics Market Report - Streamlining Drug Development and Advancing Personalized Medicine
10. Companion Diagnostics Market, 2012-2023
11. Companion 2 Hospital Driver for Powering SynCardia Total Artificial Heart Wins Silver at Medical Design Excellence Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016   Bay Area Lyme Foundation ... Dean Center for Tick Borne Illness , Harvard ... MIT Hacking Medicine, University of California, Berkeley, and ... the five finalists of Lyme Innovation , ... than 100 scientists, clinicians, researchers, entrepreneurs, and investors ...
(Date:6/24/2016)... 24, 2016 Research and ... "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" report ... In-Mold Electronics, Smart Skin, Structural Health Monitoring, ... Structural electronics involves electronic and/or electrical components ... replacing dumb structures such as vehicle bodies or ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ) ... medical devices and wearable sleep respiratory products in ... with Hongyuan Supply Chain Management Co., Ltd. (hereinafter referred ... to develop Dehaier,s new Internet medical technology business. ... Hongyuan Supply Chain,s sales platform to reach Dehaier,s dealers ...
Breaking Medicine Technology:
(Date:6/27/2016)... , ... June 27, 2016 , ... TopConsumerReviews.com recently awarded ... Eyeglasses . , Millions of individuals in the United States and Canada wear ... a way to both correct vision and make a fashion statement. Even celebrities use ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
Breaking Medicine News(10 mins):